Tenderwize
Retour à la recherche

Raltegravir 600 mg Drug Discount Agreement

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2028 · 672 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Raltegravir 600 mg (ATC-Code nach WHO: J05AJ01)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed volumes; actual purchases depend on prescription behavior and patient numbers.

Buyer may terminate open-house if exclusive agreements are concluded (typically 8-12 months after publication), ending...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Supply of pharmaceutical product Raltegravir 600 mg (ATC J05AJ01)
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Afficher le résumé complet

This tender is for non-exclusive drug discount agreements (Rabattvereinbarungen) under §130a Abs. 8 SGB V for the active substance Raltegravir 600 mg (ATC J05AJ01) via an open-house model. The buyer is AOK PLUS, a German health insurance fund. The agreement is a framework agreement with no guaranteed minimum purchase volumes. The contract runs until June 30, 2028, and the procedure allows any qualified pharmaceutical company to participate at any time by meeting the eligibility criteria. No estimated value is provided, and the award is not based on typical procurement criteria. The notice explicitly states it is not a standard EU procurement but published for transparency.

Risques

No guaranteed volumes; actual purchases depend on prescription behavior and patient numbers.

Buyer may terminate open-house if exclusive agreements are concluded (typically 8-12 months after publication), ending...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical enterprise as defined in §4 Abs. 18 AMG
  • Must not be subject to EU sanctions against Russia (Regulation 833/2014)

Eligibility

  • Must submit self-declaration on exclusion grounds (§§123, 124 GWB)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Raltegravir 600 mg Drug Discount Agreement

Non-exclusive discount agreement for Raltegravir 600 mg (ATC J05AJ01) under an open-house model. No minimum quantities guaranteed. Delivery to Saxony and Thuringia, Germany.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 30, 2028

Détails de la procédure

Date de publication
07 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
236436-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30